Effect of tiotropium/olodaterol on sedentary and active time in patients with COPD: post hoc analysis of the VESUTO^® study [Erratum]

Click to increase image sizeClick to decrease image size

This article refers to:

Effect of tiotropium/olodaterol on sedentary and active time in patients with COPD: post hoc analysis of the VESUTO® study

Supplementary materials

Figure S1 The effect of tiotropium/olodaterol combination therapy versus tiotropium monotherapy on time spent in 1.0–1.5 METs (A), ≥2.0 METs (B), and ≥3.0 METs (C) activity levels (percent change from baseline) by subgroup.

Abbreviations: BMI, body mass index; CI, confidence interval; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GOLD, global initiative for chronic obstructive pulmonary disease; IC, inspiratory capacity; METs, metabolic equivalents; mMRC, modified Medical Research Council; SGRQ, St George’s Respiratory Questionnaire; Tio, tiotropium; T+O, tiotropium/olodaterol.

Figure S2 The relationship between improvements in lung function and duration of 1.0–1.5 METs (A), ≥2.0 METs (B), and ≥3.0 METs (C) activity levels (percent change from baseline).

Abbreviations: CI, confidence interval; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; IC, inspiratory capacity; METs, metabolic equivalents; Tio, tiotropium; T+O, tiotropium/olodaterol.

Figure S3 Improvement in physical activity in patients with and without FEV1 response. FEV1 ≥100 mL was defined as the minimal clinically important difference (between tiotropium/olodaterol combination therapy and tiotropium monotherapy).

Abbreviations: FEV1, forced expiratory volume in 1 s; METs, metabolic equivalents.